hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06346470, orgStudyIdInfo id: 3430-12, briefTitle: The Effect of Web-Based Breast Self-Examination Education, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Istanbul University - Cerrahpasa (IUC), class: OTHER, descriptionModule briefSummary: Breast cancer is the most common type of cancer among women. Reasons such as diagnosing breast cancer at an early stage increases the chances of treatment and survival, and the fact that the masses are largely noticed by the individual themselves, point to the importance of breast self-examination (BSE) . BSE skill is among the nursing skills. When the literature was examined, it was seen that the web-based education method was frequently used for cognitive skills during nursing education, but its use was limited for psychomotor skills training. It was determined that in BSE training, in addition to traditional education, methods such as concept maps and peer-supported education were used, but web-based education methods were not used. It is thought that the study will contribute to the literature in these aspects., conditionsModule conditions: Education, conditions: Breast Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 88, type: ESTIMATED, armsInterventionsModule interventions name: Web-based breast self examination education, outcomesModule primaryOutcomes measure: Skill and Knowledge of BSE, primaryOutcomes measure: Attitude of Web-Based Education, primaryOutcomes measure: Self-Directed Learning Skills, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Florence Nightingale Faculty of Nursing, status: RECRUITING, city: Istanbul, state: Şişli, zip: 34381, country: Turkey, contacts name: Olga İncesu, PhD, role: CONTACT, phone: 05334942989, email: olga.incesu@iuc.edu.tr, contacts name: Olga İncesu, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Öykü Kara, Msc, role: SUB_INVESTIGATOR, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06346431, orgStudyIdInfo id: 20240301, briefTitle: Efficacy of Digital Problem Solving Application in Reduction of Anxiety, Depression and Substance Use Disorder Symptoms, acronym: Efficacy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2026-03, primaryCompletionDateStruct date: 2026-11, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: 7 Generation Games, class: INDUSTRY, descriptionModule briefSummary: The focus of this study is the impact of usage of a mobile application to support problem-solving therapy on symptoms of anxiety, depression and substance use., conditionsModule conditions: Anxiety, conditions: Depressive Symptoms, conditions: Substance Use Disorders, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: DSPT - Digital Support for Problem-solving Therapy, outcomesModule primaryOutcomes measure: Generalized Anxiety Disorder Scale-7, primaryOutcomes measure: Center for Epidemiological Studies Depression Scale, primaryOutcomes measure: Drug Abuse Screening Test, primaryOutcomes measure: Michigan Alcohol Screening Test, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06346418, orgStudyIdInfo id: PNRR-MR1-2022-12376622, briefTitle: Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-19, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-05, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, class: OTHER, collaborators name: Istituto Auxologico Italiano, collaborators name: Università degli Studi della Campania Luigi Vanvitelli, collaborators name: Federico II University, descriptionModule briefSummary: Pathogenic variants in subcortical maternal complex (SCMC) have been identified not only in mothers of Beckwith-Wiedemann syndrome (BWS) babies but also in women with reproductive disturbances such as failed pregnancy attempts and recurrent pregnancy loss. Based on the higher incidence of BWS in children born from Assisted Reproductive Technology (ART), this project aims to investigate incidence and molecular mechanism of pathogenic variants of SCMC in women with reproductive disorders. Study objectives will be (i) assess the incidence of these variants as a cause of differences in reproductive outcomes in the infertile female population and mothers of children with BWS; (ii) identify methylation changes in women with reproductive problems including those with offspring affected by BWS; (iii) determine the molecular causes underlying female infertility and imprinting disorder associated with damaging SCMC gene variants by employing a mouse model., conditionsModule conditions: Beckwith-Wiedemann Syndrome, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 208, type: ESTIMATED, armsInterventionsModule interventions name: WES analysis, interventions name: whole-genome methylation analysis, outcomesModule primaryOutcomes measure: MEG Incidence, secondaryOutcomes measure: Compare DNA methylation, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, status: RECRUITING, city: Milan, zip: 20122, country: Italy, contacts name: Edgardo Somigliana, PhD, role: CONTACT, phone: +390255034303, email: edgardo.somigliana@policlinico.mi.it, geoPoint lat: 45.46427, lon: 9.18951, locations facility: Istituto Auxologico Italiano, status: RECRUITING, city: Milan, zip: 20145, country: Italy, contacts name: Silvia Russo, Phd, role: CONTACT, phone: +393493237520, email: s.russo@auxologico.it, geoPoint lat: 45.46427, lon: 9.18951, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2022-12-20, uploadDate: 2024-03-28T05:11, filename: Prot_SAP_000.pdf, size: 817568, hasResults: False
protocolSection identificationModule nctId: NCT06346405, orgStudyIdInfo id: 10, briefTitle: Central Serous Chorioretinopathy and Micropulse Laser Treatment, acronym: LEVEO, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-31, primaryCompletionDateStruct date: 2025-05-31, completionDateStruct date: 2025-05-31, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone, conditionsModule conditions: Central Serous Chorioretinopathy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 36, type: ESTIMATED, armsInterventionsModule interventions name: Subthreshold Micropulse Laser Treatment, outcomesModule primaryOutcomes measure: Vessel density changes, secondaryOutcomes measure: Choroidal thickness, secondaryOutcomes measure: Choroidal thickness and vessel density, secondaryOutcomes measure: Qualitative analysis of retino-choroidal vascularization with identification of vascular pattern, secondaryOutcomes measure: Metamorphopsia, secondaryOutcomes measure: Metamorphopsia and BCVA, secondaryOutcomes measure: Ellipsoid Zone Integrity, secondaryOutcomes measure: Improvement in retinal function, secondaryOutcomes measure: Quality of life (QoL), secondaryOutcomes measure: Ellipsoid zone and BCVA, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fondazione Policlinico Agostino Gemelli, IRCCS, status: RECRUITING, city: Roma, state: R, zip: 00168, country: Italy, contacts name: Maria Cristina Savastano, MD, PhD, role: CONTACT, phone: (+39)063015, email: mariacristinasavastano@policlinicogemelli.it, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06346379, orgStudyIdInfo id: 2023-K086-01, briefTitle: The Effect of Baduanjin on Physical Fitness and Bone Density in Maintenance Hemodialysis Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2025-10-01, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Affiliated Hospital of Nantong University, class: OTHER, descriptionModule briefSummary: The aim of this study is to examine the effect of 12-month Baduanjin exercise on physical fitness and bone density in maintenance hemodialysis (MHD) patients. 50 MHD patients aged 18-75 will included in this study and randomly divided into two groups (intervention group and control group). The intervention group will be led by a professional person and underwent Baduanjin exercise three times a week before hemodialysis. The control group maintained routine treatment and daily activities., conditionsModule conditions: Rehabilitation, conditions: Physical Fitness, conditions: Bone Density, conditions: Hemodialysis Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Baduanjin exercise, outcomesModule primaryOutcomes measure: Muscle strength measurement, primaryOutcomes measure: Five-times Sit-to-Stand Test (FTSST), primaryOutcomes measure: Timed "up and go" test (TUGT), primaryOutcomes measure: The sitting forward flexion test, primaryOutcomes measure: The Standing on one-leg with eyes closed test (SOLECT), primaryOutcomes measure: Bone mineral density test, secondaryOutcomes measure: Changes in the Short Form-36(SF-36), secondaryOutcomes measure: Changes in the Hospital Anxiety and Depression Scale （HADS）, secondaryOutcomes measure: European Quality of Life Five Dimension（EQ-5D-5L), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Affiliated Hospital of Nantong University, status: RECRUITING, city: Nantong, state: Jiangsu, zip: 226000, country: China, contacts name: Li Yuan, role: CONTACT, phone: 0086-051381168416, email: yuanlint@163.com, contacts name: Yuan Zhang, role: CONTACT, phone: 0086-051381168411, email: 49260183@qq.com, geoPoint lat: 32.03028, lon: 120.87472, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-07-10, uploadDate: 2024-03-18T04:22, filename: Prot_SAP_000.pdf, size: 179776, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2023-07-10, uploadDate: 2024-03-28T03:53, filename: ICF_001.pdf, size: 247762, hasResults: False
protocolSection identificationModule nctId: NCT06346353, orgStudyIdInfo id: Chess Cognition SUD, briefTitle: Substance Consumption, Personality, and Cognitive Functioning of Chess Players, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-31, primaryCompletionDateStruct date: 2024-05-31, completionDateStruct date: 2024-05-31, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Central Institute of Mental Health, Mannheim, class: OTHER, descriptionModule briefSummary: The aim of this project is to find out if there is a difference in addictive behavior, personality traits, and cognitive abilities between chess players and non-chess players., conditionsModule conditions: Addiction, conditions: Alcohol, conditions: Nicotine, conditions: Drugs, conditions: Personality, conditions: Depression, conditions: Anxiety, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 910, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Substance Craving, primaryOutcomes measure: Alcohol Use, primaryOutcomes measure: Automatic Alcohol Craving, primaryOutcomes measure: Severity of Nicotine Dependence, primaryOutcomes measure: Automatic Cigarette Craving, primaryOutcomes measure: Smoking Consequences, primaryOutcomes measure: Drug Abuse, primaryOutcomes measure: Personality, primaryOutcomes measure: Depression, primaryOutcomes measure: Anxiety, primaryOutcomes measure: self-efficacy, primaryOutcomes measure: coping with stress, primaryOutcomes measure: Inhibition capacity, primaryOutcomes measure: Working Memory capacity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Klinik für Abhängiges Verhalten, Zentralinstitut für Seelische Gesundheit, status: RECRUITING, city: Mannheim, country: Germany, contacts name: Sabine Vollstädt-Klein, role: CONTACT, geoPoint lat: 49.4891, lon: 8.46694, hasResults: False
protocolSection identificationModule nctId: NCT06346340, orgStudyIdInfo id: 936, briefTitle: A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-11, primaryCompletionDateStruct date: 2024-09, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Bausch & Lomb Incorporated, class: INDUSTRY, descriptionModule briefSummary: A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy, conditionsModule conditions: Dry Eye, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Miebo, outcomesModule primaryOutcomes measure: Mean difference between absolute deviations from predicted refractive error in the study eye., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Site 105, city: Laguna Hills, state: California, zip: 92655, country: United States, geoPoint lat: 33.61252, lon: -117.71283, locations facility: Site 102, city: Petaluma, state: California, zip: 92954, country: United States, geoPoint lat: 38.23242, lon: -122.63665, locations facility: Site 103, city: Largo, state: Florida, zip: 33770, country: United States, geoPoint lat: 27.90979, lon: -82.78842, locations facility: Site 104, city: Saint Louis, state: Missouri, zip: 63131, country: United States, geoPoint lat: 38.62727, lon: -90.19789, locations facility: Site 101, city: Somersworth, state: New Hampshire, zip: 03878, country: United States, geoPoint lat: 43.26175, lon: -70.86534, hasResults: False
protocolSection identificationModule nctId: NCT06346327, orgStudyIdInfo id: Absent End-Diastolic Flow, briefTitle: Clinical Significance Of Intermittently Absent End-Diastolic Flow Of The Fetal Umbilical Artery On Perinatal And Neonatal Outcomes Dr. Zeynep Kayaoğlu Yıldırım Dr. Alperen İnce Dr Gökhan Bayanmelek Dr Gökhan Bolluk, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-06-01, primaryCompletionDateStruct date: 2023-08-31, completionDateStruct date: 2023-10-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Başakşehir Çam & Sakura City Hospital, class: OTHER_GOV, descriptionModule briefSummary: Objective: This study aimed to estimate the risk of adverse perinatal outcomes among pregnant patients with intermittently absent (iAEDF) and persistently absent end-diastolic umbilical artery flow (pAEDF). The fetal risks associated with persistently absent end-diastolic flow have been described. However, the risks associated with intermittent absent end-diastolic flow are not well-known.Study design: We performed a retrospective cohort study of patients diagnosed with the iAEDF or pAEDF at our institution from 2020 to 2023. Fetuses were classified under two categories: iAEDF group and pAEDF group.Neonatal outcomes, demographic information, pregnancy outcomes and pregnancy complications were compared between patients with iAEDF and those with pAEDF., conditionsModule conditions: Absent End-Diastolic Flow Of The Fetal Umbilical Artery, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 137, type: ACTUAL, outcomesModule primaryOutcomes measure: neonatal outcomes, primaryOutcomes measure: latency from the time of absent endiastolic flow diagnosis to delivery, primaryOutcomes measure: pregnancy complications (Number of Pregnancies complicated with IUMF, ablatio placenta, fetal distress, Intrauterine growth restriction and amniotic fluid abnormalities)., eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: İstanbul Başakşehir Çam ve Sakura City Hospital, city: Istanbul, state: Türkiye, zip: 34480, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-11-08, uploadDate: 2024-04-02T18:47, filename: Prot_SAP_000.pdf, size: 410898, hasResults: False
protocolSection identificationModule nctId: NCT06346314, orgStudyIdInfo id: 12241976, briefTitle: Is There an Immediate Effect on Pectoralis Minor Length After Performing a Prone Scapular Retraction Exercise, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-07-15, primaryCompletionDateStruct date: 2022-01-10, completionDateStruct date: 2022-01-10, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Andrews University, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to test normal participants.The main question it aims to answer is:• Do the participant's pectoralis minor muscles change length immediately after performing an exercise that recruits the scapular retractor muscles? Participants will have their pectoralis minor muscle measured, then perform an exercise recruiting the scapular retractor muscles, and then have their pectoralis muscle measured again., conditionsModule conditions: Pectoralis Minor Length, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ACTUAL, armsInterventionsModule interventions name: Scapular retraction exercise, outcomesModule primaryOutcomes measure: Pectoralis Minor Length, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: North Idaho Physical Therapy, city: Hayden, state: Idaho, zip: 83835, country: United States, geoPoint lat: 47.76602, lon: -116.78658, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-11-30, uploadDate: 2023-11-30T13:36, filename: Prot_SAP_000.pdf, size: 341703, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2021-04-19, uploadDate: 2024-03-12T17:52, filename: ICF_001.pdf, size: 286800, hasResults: False
protocolSection identificationModule nctId: NCT06346288, orgStudyIdInfo id: M24-144, briefTitle: A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-06, primaryCompletionDateStruct date: 2025-01-20, completionDateStruct date: 2025-05-27, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: AbbVie, class: INDUSTRY, descriptionModule briefSummary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease that requires lifelong treatment. This study will asses the concentrations of risankizumab in the breast milk of lactating women with IBDRisankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and Crohn's Disease. This is an open-label milk-only study lactation study to evaluate the presence of risankizumab in the milk of lactating women. Approximately 10 adult lactating women with IBD will be enrolled from approximately 3 sites in Israel and or the United States.Participants will receive risakizumab maintenance therapy every 8 weeks postpartum prior to start of participation in this study. The study duration is approximately 7 months.Participants will attend regular visits during the study at a hospital or clinic. The participants will also be completing questionnaires and will have medical assessments, checking for side effects., conditionsModule conditions: Inflammatory Bowel Disease, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: The study will only include lactating women who are receiving treatment with risankizumab for IBD in accordance with their treating physician, although this study is non-interventional regarding treatment with risankizumab, it is considered interventional due to the collection of breast milk from the lactating mothers., primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Breast Milk Sampling, interventions name: Risankizumab, outcomesModule primaryOutcomes measure: To determine the concentration of risankizumab in breastmilk, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False